SENSIMED Triggerfish
DeviceContact lens-based device for continuous intraocular pressure monitoring
NCT Number: NCT01217853
A study in which intraocular pressure (IOP) will be monitored over 24 hours using the SENSIMED Triggerfish® device and Goldmann applanation tonometry (GAT) in primary open angle glaucoma patients. The aim of this study is to investigate the comparability of diurnal IOP patterns emerging from SENSIMED Triggerfish and GAT.
Looking for future studies?
Notify Me40 year–70 year
All sexes
Observational
Schlosspark-Klinik, Berlin, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Contact lens-based device for continuous intraocular pressure monitoring
Time frame: During 24 hours
Patients will undergo one session of 24-hour SENSIMED Triggerfish continuous intraocular pressure monitoring in one eye.
Time frame: During 24 hours
Goldmann applanation IOP readings will be done in the other eye at regular intervals during 24-hour SENSIMED Triggerfish IOP monitoring and in both eyes during another 24-hour session.
Sensimed AG
Industry
Comparison of 24-hour Continuous IOP Monitoring With a Contact Lens-based Sensor to Goldmann Applanation Tonometry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06144918
Eye Diseases, Glaucoma
Glendale, California, United States
View Trial DetailsNCT06978101
Chorioretinal Changes, Eye Diseases
Asyut, Egypt
View Trial DetailsNCT04830397
Eye Diseases, Glaucoma
Albany, Georgia, United States
View Trial DetailsNCT06745856
Eye Diseases, Glaucoma
View Trial Details